Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders

LAGUNA HILLS, Calif.: LAGUNA HILLS, Calif., Feb. 16, 2022 /PRNewswire/ — Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company’s investigational new drug (IND) application to conduct human studies using Resolv ER™ for the treatment of Vitreomacular Attachment (VMA). This first-in-class patented…